Abstract
AbstractHepatocellular carcinoma (HCC) is one of the leading cancer-related deaths worldwide. Recently, studies for HCC treatment are focused on cancer immunotherapy, particularly cancer vaccines, to complete and assist other therapies. TPX2 is a microtubule-associated protein necessary for cell division; therefore, alteration in its expression, especially up regulation, is associated with several human carcinomas such as HCC.In this study, immunoinformatics tools were used to design a rational multi-epitope T vaccine against TPX2 in HCC. Cytotoxic T lymphocytes (CTL) and Helper T lymphocytes (HTL) epitopes were predicted and Maltose-binding protein (MBP) was added to the construct as an adjuvant. Evaluation of vaccine properties was indicated that our construct is stable and immunogenic enough to induce relevant responses besides not being allergic. After predicting the tertiary structure and energy minimization, protein-protein docking was performed to calculate the free energy of possible interactions between the vaccine and toll-like receptor 4 (TLR4) to assure that simultaneous complementary responses would be activated by our construct. Finally, Codon optimization and in-silico cloning were performed to ensure the vaccine expression efficiency in the desired host.
Publisher
Cold Spring Harbor Laboratory
Reference41 articles.
1. W.H.O, “Cancer,” World Health Organization. 2015.
2. A. Gurakar , J. P. Hamilton , A. Koteish , Z. Li , and E. Mezey , “Hepatocellular Carcinoma (Liver Cancer): Introduction,” 2001.
3. M. Ringelhan , D. Pfister , T. O’Connor , E. Pikarsky , and M. Heikenwalder , “The immunology of hepatocellular carcinoma,” Nat. Immunol., 2018.
4. Inflammatory Immune Responses in Tumor Microenvironment and Metastasis of Hepatocellular Carcinoma
5. Y. Xie , Y. Xiang , J. Sheng , D. Zhang , X. Yao , Y. Yang , and X. Zhang , “Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations,” J. Immunol. Res., 2018.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献